Skip to main content
Top

2008 | OriginalPaper | Hoofdstuk

7 Bewijs toepassen op individuele patiënten

Auteurs : Prof. dr. M. Offringa, Dr. P. P. G. van Benthem, Dr. S. Middeldorp

Gepubliceerd in: Inleiding in evidence-based medicine

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

In de definitie van evidence-based medicine (het zorgvuldig, expliciet en oordeelkundig gebruik van het huidige beste bewijsmateriaal om beslissingen te nemen voor individuele patiënten) wordt gesproken over individuele patiënten.
Literatuur
1.
go back to reference Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ’number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002 Feb;31(1):72-6. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ’number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002 Feb;31(1):72-6.
2.
go back to reference Glasziou PP, Irwig LM. An evidence based approach to individualizing treatment. BMJ 1995;311:135-69. Glasziou PP, Irwig LM. An evidence based approach to individualizing treatment. BMJ 1995;311:135-69.
3.
go back to reference Levi M, Hovingh GK, Cannegieter SC, Vermeulen MR, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K-antagonists that would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008 May;111(9):4471-6. Levi M, Hovingh GK, Cannegieter SC, Vermeulen MR, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K-antagonists that would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008 May;111(9):4471-6.
4.
go back to reference Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, Dongen CJ van, Middeldorp S, Bank I, Meer J van der, Hamulyák K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004 Dec;92(6):1336-41. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, Dongen CJ van, Middeldorp S, Bank I, Meer J van der, Hamulyák K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004 Dec;92(6):1336-41.
5.
go back to reference Lubsen J, Tijssen JG. Large trials with simple protocols: Indications and contraindications. Control Clin Trials 1989;10:151S-60S. Lubsen J, Tijssen JG. Large trials with simple protocols: Indications and contraindications. Control Clin Trials 1989;10:151S-60S.
6.
go back to reference Sont JK, Stiphout WA van, Noordijk EM, Molenaar J, Zwetsloot-Schonk JH, Willemze R, Vandenbroucke JP. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience. Ann Hematol 1992 Nov;65(5):213-8. Sont JK, Stiphout WA van, Noordijk EM, Molenaar J, Zwetsloot-Schonk JH, Willemze R, Vandenbroucke JP. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience. Ann Hematol 1992 Nov;65(5):213-8.
Metagegevens
Titel
7 Bewijs toepassen op individuele patiënten
Auteurs
Prof. dr. M. Offringa
Dr. P. P. G. van Benthem
Dr. S. Middeldorp
Copyright
2008
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-6636-1_7